Literature DB >> 12609674

Potential of capillary electrophoresis for the monitoring of the stability of placental alkaline phosphatase.

H J C Eriksson1, M Wijngaard, W L J Hinrichs, H W Frijlink, G W Somsen, G J de Jong.   

Abstract

Alkaline phosphatase (AP) is a potential therapeutic agent in the treatment of sepsis. In this paper the potential of capillary zone electrophoresis (CZE) for the monitoring of the degradation of placental alkaline phosphatase (PLAP) was investigated. To induce degradation PLAP samples were exposed to high temperatures, low and high pH and freeze-drying. The samples were then analyzed by CZE and enzymatic activity assay. Upon exposure to temperatures above 65 degrees C, PLAP lost its activity exponentially over time, while CZE revealed both a linear decrease of the area of the main peak and a rise of degradation products. At acidic pH the enzyme appeared to lose its activity. CZE revealed a decrease of the area of the main peak, but no degradation products could be detected. At pH 12 the enzymatic activity and the area of the main peak both decreased linearly over time and, in addition, formation of degradation products could be detected by CZE. Activity and CZE profile of PLAP remained unchanged upon freeze-drying in the presence of inulin. Prolonged storage of freeze-dried samples at room temperature caused a slight decrease of enzymatic activity, while the potential formation of oligomers was revealed by CZE analysis. The examples in this study show that, in combination with activity assays, CZE can provide useful complementary information, especially on the status of the protein and the presence of degradation products.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12609674     DOI: 10.1016/s0731-7085(02)00646-5

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  1 in total

1.  Investigations into the stabilization of drugs by sugar glasses: III. The influence of various high-pH buffers.

Authors:  Jonas H C Eriksson; Wouter L J Hinrichs; Gerhardus J de Jong; Govert W Somsen; Henderik W Frijlink
Journal:  Pharm Res       Date:  2003-09       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.